Kornimate/medical-research-clean huggingface dataset:
effect of soaking complementary foods flour on hemoglobin concentration, anthropometric deficits and episode of diarrheal, cough and fever morbidities

Conditions: Anemia

Summary: removing anti nutrient factors using simple cost-effective and sustainable household methods to improve nutritional status of children in communities were plant based complementary foods are the main source of nutrients is highly recommended. therefore, the aim of this study is to determine effect of soaking complementary foods on hemoglobin, nutritional and health status of children 6-23 months in agrarian community of bale zone.

objectives of the intervention * to determine prevalence and associated factors of nutritional status and anemia among children aged 6-23 months in agrarian community of bale zone * to explore the complementary feeding practice knowledge perception of mother with children aged 6-23 months in agrarian community of bale zone * to determine effect of soaking complementary foods flour on nutritional status of children aged 6-23 months in agrarian community of bale zone * to determine effect of soaking complementary foods flour on hemoglobin level of children aged 6-23 months in agrarian community of bale zone * to determine effect of soaking complementary foods flour on frequency of morbidity of children aged 6-23 months in agrarian community of bale zone target groups the target groups for the intervention will be mothers with their children aged 6-23 months in selected districts of bale zone and participated in the baseline study. following baseline study, the two districts were assigned to be either an intervention or comparison group randomly. while the intervention community received the nutrition counselling on promotion of complementary flour soaking, the comparison community was monitored for presence of any other intervention that might have a potential to mask the effect of the current intervention in the target. the intervention will be carried out for a period of six months. end-line data collection included the following major components: * dietary diversity practice * anthropometric measurements * hemoglobin test

Eligibility criteria:
inclusion criteria: * voluntarily agreed mothers with children aged 6-23 month * mothers with children aged 6-23 month who lived at least six months in the selected communities * mothers who have no plan to leave the area within 6 months period exclusion criteria: * • if the child is seriously ill at the time of data collection * children with severe anemia hemoglobin level \<= 7mg/dl will be excluded

Keywords: complementary feeding soaking flours undernutrition anemia
the effect of a low glycemic index diet on blood sugar control in women with gestational hyperglycemia

Conditions: Gestational Diabetes

Summary: the purpose of the study is to see if a low glycemic index diet will reduce blood sugar levels in pregnant women with high blood sugar levels.

women with gestational hyperglycemia, including women with gestational diabetes and impaired glucose tolerance of pregnancy, consuming a low glycemic index (gi) diet will experience better blood glucose control thereby decreasing the risk associated complication(s).

Eligibility criteria:
inclusion criteria: * women with gestational hyperglycemia * age between 18 and 45 inclusive * willing and able to comply with protocol exclusion criteria: * \ 45 years of age * other chronic or acute illness which affects carbohydrate metabolism * known multiple pregnancy * \>34 weeks gestation * language barrier (no translator available)
realizing effectiveness across continents with hydroxyurea

Conditions: Sickle Cell Disease; Children

Summary: reach is a prospective, phase i/ii open-label dose escalation trial of hydroxyurea for children with confirmed sca between 3 and 10 years of age. the short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with sca in multiple distinct research settings in africa. based on that information, the longer-term goal is to make hydroxyurea more widely available for children with sca in africa, particularly those identified with sca through expanded newborn screening programs.

reach is a prospective, phase i/ii open-label dose escalation trial of hydroxyurea for children with confirmed sca between 3 and 10 years of age. the short-term goal is to obtain critical pilot data regarding the feasibility, safety, and benefit of hydroxyurea for children with sca in multiple distinct research settings in africa. based on that information, the longer-term goal is to make hydroxyurea more widely available for children with sca in africa, particularly those identified with sca through expanded newborn screening programs. in the reach prospective trial, the original cohort will receive long-term treatment while for the new cohort, treatment will continue at least 4 years using pk-guided dosing after an initial 3-month screening period.

Eligibility criteria:
inclusion criteria 1. pediatric patients with documented sickle cell anemia (typically hbss supported by hemoglobin electrophoresis, complete blood count, and peripheral blood smear) 2. in the original cohort, age range of 1.00-9.99 years, inclusive, at the time of enrollment (now age 5.5 - 17.5 years); age range 3.0-10.0 years for the new cohort 3. weight at least 10.0 kg at the time of enrollment 4. parent or guardian willing and able to provide written informed consent, with child's verbal assent as per local irb/ethics board requirements 5. willingness to comply with all study-related treatments, evaluations, and follow-up exclusion criteria 1. known medical condition making participation ill-advised (e.g., acute or chronic infectious disease, hiv, or malignancy) 2. acute or chronic severe malnutrition determined by impaired growth parameters as defined by who (weight for length/height or height for age \>3 z-scores below the median who growth standards. 3. pre-existing severe hematological toxicity (temporary exclusions) 1. anemia: hb \<4.0 g/dl 2. anemia: hb \<6.0 g/dl with arc \<100 x 109/l 3. reticulocytopenia: arc \<80 x 109/l with hb \<7.0 g/dl 4. thrombocytopenia: platelets \<80 x 109/l 5. neutropenia: anc \<1.0 x 109/l 4. blood transfusion within 60 days before enrollment (temporary exclusion) 5. in the original cohort, hydroxyurea use within 6 months before enrollment (temporary exclusion). in the new cohort, the children should be hydroxyurea naïve, without any prior treatment exposure.
impact of football matches on the emergency admissions of a level iii maternity during euro 2016

Conditions: Gynecologic Disease

Summary: attendances at an emergency department (ed) are often considered to depend on different factors such as moonlight, welfare checks, weather, and major sporting events. data regarding effects of large sporting events on the workload of ed often assessed decreased patient volume, especially male use. currently, no data are available on the effect of major televised sporting events on obstetrical visits. the aim of this study is to examine whether televised soccer games from a major sporting tournament, (euro 2016) influence the level of attendance at an obstetrical ed and could have implications for women's welfare. in the summer of 2016, france hosted the largest european sporting event of the year 2016: the european football championships (euro 2016). a total of 51 games were played over a month, bringing together the biggest european teams. an observational, retrospective study is conducted during this period on the number of emergency visits in a french tertiary maternity hospital (maternity of nancy).


Eligibility criteria:
inclusion criteria: all female patients admitted urgently to the regional maternity hospital between june 10 and july 10, 2016 exclusion criteria: * refusal of the patient * information and understanding impossible
a clinical study of truview art™(advanced reconstruction tech)to improve image quality on chest radiograph

Conditions: Thoracic Diseases

Summary: to validate the following theory: "with truview art™ applied a detector's quantitative performance index, mtf(modulation transfer function), is increased 20% or more". this is to examine the effect of the increased mtf index, whether it influences or not the interpreter's preference

background of study : drtech corp. has developed and applied for patenting the unique technology of truview art™. truview art™ is advanced image reconstruction technology that restores image quality from the side effects of scattering signals in indirect type scintillator detectors. it is an advanced image pre-processing technology that constructs signal scattering models (psf) of indirect type detector scintillators. image sharpness (mtf) is improved by predicting scattering models and eliminating the scattering signal. purpose of research and assumption : indirect conversion type detectors using scintillators are universal in today's diagnostic imaging area. however, they have a disadvantage of signal scattering compared with direct conversion type detectors. truview art™(advanced reconstruction technology) can restore images from the scattering problems. the purpose of this study is to verify how well it improves the usefulness in clinical diagnostic imaging. evaluation will measure the improvements in mtf, which is the quantitative performance index of a detector.

Eligibility criteria:
inclusion criteria: * adults of age 20 or higher * person who is able to fully understand the clinical research procedures * signed up agreement form * patient who visits for chest computed tomography (ct) exclusion criteria: * subject is pregnant or suspicious of being pregnant * not able or willing to provide informed consent, or consent is withdrawn * not able to collect all required case information

Keywords: chest radiography image improvements image reconstruction preprocessing mtf
paravertebral catheter for lung transplant

Conditions: Acute Pain

Summary: this is a prospective observational trial of patient undergoing lung transplantation who have a thoracic paravertebral catheter(s) placed for postoperative pain control. patients pain scores and opioid use were evaluated for 7 days after placement as well as any complications, opioid adverse events, and length of stay.

following approval of the university of minnesota institutional review board, 33 consecutive adult patients (≥ 18 years of age) were observed from october 2013 to december 2014 who underwent either single or bilateral lung transplantation and received a continuous paravertebral block. the paravertebral catheters were placed within 1-2 day postoperatively in the intensive care unit. if the patient was too hemodynamically unstable or too critically ill to be placed in lateral decubitus position, the placement of the catheter was delayed or in some cases not performed (these patients were not included in study) they were placed via an in plane transverse technique. the ultrasound was placed on the patient's back at the t8-9 level with probe in transverse orientation. then a 17-gauge tuohy needle was advanced lateral to medial in plane until beneath the transverse process upon which a test dose of 3-5 ml of 1.5% lidocaine with 1:200,000 epinephrine was injected to see adequate spread. the catheter was then fed 1 centimeter past the tip of the tuohy needle and needle was withdrawn. all catheters were confirmed to be in correct position with real time local anesthetic injection and secured with skin glue and occlusive dressing. each was performed with the patient in the left lateral decubitus position for the right catheter and right lateral decubitus position for the left catheter. the paravertebral catheters remained in place for up to seven days postoperatively in unilateral lung transplants and up to ten days postoperatively in bilateral lung transplants. during that time an infusion of 0.2% ropivacaine was infused at a rate of 0.2-0.25 ml/kg/hour through an elastomeric pump (on q halyard health). the outcome measured were minimal and maximum pain scores from the first 7 days post paravertebral catheter placement (rated on an 11-point numeric rating scale; 0=no pain, 10=worst pain imaginable). the acute pain nurse practitioners, bedside nurses, or acute pain anesthesiology residents collected the pain scores. additional outcomes of interest included postsurgical opioid use through postsurgical day 7, and length of hospital stay. patients were asked daily if they experienced nausea/vomiting, however, nursing notes and physician progress notes were also evaluated if patients experienced any adverse events or nausea and vomiting. demographics such as age and weight were recorded in addition to length of surgery and time spent in the hospital before discharge.

Eligibility criteria:
inclusion criteria: * lung transplant * clamshell incision * received paravertebral catheter within 2 days of surgery exclusion criteria: * non english speaking * remained intubated for greater than 3 days postoperatively * midline incision * allergy to local anesthetics
the efficacy of low dose naltrexone therapy in children with crohn's disease

Conditions: Crohn's Disease

Summary: it is hypothesized that oral naltrexone will improve inflammation of the bowel by increasing endogenous enkephalin levels in subjects with active crohn's disease. this is especially important in children who often are suffering from nutritional deprivation which retards their growth. the key objectives are to: 1. evaluate the effects of low dose naltrexone in children with crohn's disease by using the pediatric crohn's disease activity index (pcdai), plasma inflammatory markers, weight, and pediatric quality of life survey. 2. to determine the safety and toxicity of low dose naltrexone in pediatric subjects with active crohn's disease. 3. assess the potential mechanism by which naltrexone exerts its action by measuring plasma opioid (enkephalin and endorphin levels) and proinflammatory cytokines.

the present proposal is designed as double-blinded placebo controlled study involving 30 children between 6-17 years of age with active crohn's disease. children will be treated with either naltrexone or placebo for the first 8 weeks then all subjects will receive active naltrexone drug the last 8 weeks. a one month follow-up appointment will be scheduled 4-weeks after completion of the active drug for safety and to assess crohn's activity. low dose naltrexone (ldn) will be dispensed in either capsules at a dose of 4.5 mg for those ages 10 years or older and in liquid form at 0.1 mg/kg for those under age of 10 or less than 45 kg. half of the subjects in the first 8 weeks will be randomized to placebo which will be either capsules filled with avicel (see section 6.0) or diluent (flavored water) if in liquid form. children are eligible who are not of child-bearing potential or are using two means of effective birth control, have a pediatric crohn's disease activity index (pcdai) of at least 31 points, and have the confirmed diagnosis of crohn's disease by either endoscopic or radiographic tests.

Eligibility criteria:
inclusion criteria: * all subjects must give written informed consent by parent or guardian * male or female subjects, \> 6 - 17 years * patients must have endoscopic or radiographic confirmed crohn's disease. * patients must have a pediatric crohn's disease activity index (pcdai) of at least 31. exclusion criteria: * adolescent women of childbearing potential and / or sexually active unless surgically sterile or using adequate contraception (either iud, oral or deport contraceptive, or barrier plus spermicide), and willing and able to continue contraception for 3 months after the completion of the study. * adolescent women who are pregnant or breastfeeding * subjects with an ostomy or ileocolic anastomosis from surgery as these operations interfere with the pcdai assessment * subjects taking tacrolimus, cyclosporin, mycophenolate, or anti-tnf-α therapy must be discontinued 4 weeks prior to study initiation. * patients with abnormal liver function tests * prednisone greater than 10 mg or \> 0.2 mg/kg orally

Keywords: children pediatric crohn's disease naltrexone ldn ibd inflammatory bowel disease
cerebellar rtms for the treatment of schizophrenic patients

Conditions: Schizophrenia

Summary: the primary aim of this protocol is to determine whether the use of repetitive transcranial magnetic stimulation (rtms) over vermis of the cerebellum may be safe and therapeutically effective in patients with schizophrenia. because this is the first evaluation of this treatment in this population, the focus of this study is safety.


Eligibility criteria:
inclusion criteria: 1. age between 18-65 years 2. diagnosis of schizophrenia according to dsm-iv criteria(by a board-certified psychiatrist) exclusion criteria: 1. prior neurosurgical procedures 2. any history of seizure 3. previous head injury 4. contraindication to tms: 1. implanted pacemaker 2. medication pump 3. vagal stimulator 4. deep brain stimulator 5. metallic hardware in the head or scalp: shrapnel, surgical clips, or fragments from welding 6. signs of increased intracranial pressure 5. tens unit and ventriculo-peritoneal shunt 6. pregnancy or lactating; note that a negative pregnancy test will be required if the patient is a female in reproductive years 7. advanced liver, kidney, cardiac, or pulmonary disease as defined clinically or a terminal medical diagnosis consistent with survival \< 1 year 8. a history of significant alcohol or drug abuse in the prior six months 9. no focal cortical insult can be present, including tumor or vascular malformation 10. patients may not be actively enrolled in a separate intervention study 11. patients unable to undergo a brain mr: a. claustrophobia refractory to anxiolytics ferromagnetic metal in the body such as a prosthetic heart valve, a pacemaker, or a brain aneurysm clip). 12. change in antipsychotic medication during the last 4 weeks 13. any emergency psychiatry department visit during the last 4 weeks 14. been an inpatient in a psychiatry clinic within the last month 15. any other axis i diagnosis
pelvic muscle training and electrostimulation to treat weak pelvic floor

Conditions: Pelvic Floor Muscle Weakness; Incontinence Stress; Electricity; Effects; Muscle Weakness Condition

Summary: this research will determine 1) whether the very weak pelvic floor can be improved with surface electromyography (s-emg)-triggered electrostimulation added to pelvic floor muscle training and 2) whether semg-triggered electrostimulation added to pelvic floor muscle training can reduce leakage in stress urinary incontinence (sui)

among women with pelvic floor dysfunction, it has long been known that pfm training is the first-line therapy for stress incontinence. one of the difficulties that clinicians often find upon examination is that many women present a very weak pelvic floor and are unable to contract their pfm. there is overwhelming evidence to show that conservative treatment in the form of pelvic muscle exercises (and to a lesser degree, electrotherapy, and vaginal weight therapy) is effective in the treatment of stress urinary incontinence. to date, there is some evidence to support the use of electrical stimulation for stress urinary incontinence in women, but we are still very uncertain about the full potential of this treatment because of the low quality of the existing evidence.

Eligibility criteria:
inclusion criteria: * • adult women (18 years old - 50 years old), with a modified oxford score, determined by digital palpation, of 0 - 1, complaining leakage episode occurring more than once a week. * between six and eighteen months after childbirth * willing and able to be compliant with pelvic floor muscle exercise intervention (standard of care) for 12 weeks and to log compliance * willing and able to undergo an extensive physical function evaluation exclusion criteria: * • pregnancy * severe neurological disease (multiple sclerosis, parkinson's disease, spinal cord injury, major stroke or neuromuscular junction diseases) * previous operation for cancer or radiotherapy in the lower abdomen * prior surgical intervention for urinary incontinence within the past 12 months * hysterectomy within 12 months * voiding dysfunction * pelvic pain * severe prolapse (≥ grade 3) * recurrent urinary tract infection * pelvic or disseminated malignancies * women who were virgo intacta * women who declined vaginal examinations for any reasons * before four months of pregnancy * having significant cognitive impairment or dementia * unsafe to exercise (severe cardiopulmonary disease) * unable/unwilling to provide informed consent * patient has on physical examination, neurological and/or vaginal examination results which, in the opinion of the investigator, should exclude the subject.

Keywords: pelvic floor muscle weakness electrical stimulation pelvic floor muscle training
cultivated stem cell transplantation for the treatment of limbal stem cell deficiency

Conditions: Limbal Stem Cell Deficiency

Summary: the purpose of this study is to determine whether cultivated stem cell transplantation is effective for the treatment of patients wtih corneal stem cell deficiency.


Eligibility criteria:
inclusion criteria: * patients suffering from lscd iia and iib. those suffering from iic may be included once inflammation has subsided and cornea can be staged as iib. * absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. * women of child-bearing potential should use adequate contraception prior to study entry and for the duration of study participation exclusion criteria: * subjects who are pregnant or lactating * subjects who have sensitivity to drugs that provide local anesthesia * subjects suffering from active infection of the external eye * medical conditions that prohibit the use of systemic immunosuppression (in cases of allogenic transplantation)

Keywords: aniridia, steven johnsons syndrome, ocular burns, pterygium
film array gastrointestinal panel compared to usual care for ed evaluation of infectious diarrhea

Conditions: Infectious Diarrhea

Summary: this research study will test a laboratory test called film-array gastrointestinal (gi) panel. this gi panel is a test that can identify the bacteria or viruses that may cause diarrhea. this test will enable the ed doctor to better understand the cause of diarrhea to try to determine the best treatment. the primary objective of this study is to determine if testing ed patients who complain of diarrhea will lead to more optimal use of antibiotics. optimal use of antibiotics is defined as the most appropriate antibiotic to treat a specified pathogen.


Eligibility criteria:
inclusion criteria: * presumed infectious diarrhea (3 or more loose stools in past 24 hours) * must have one of the 3 following features or symptoms lasting more than 7 days. 1. symptoms greater than 24 hours; 2. dehydration (defined as the need for intravenous fluid or per clinician's judgement ((based on the general appearance and alertness of the patient, the pulse, the blood pressure, the presence or absence of postural hypotension, the mucous membranes and tears, sunken eyes, skin turgor, capillary refill, and jugular venous pressure.)) 3. inflammation (defined as fever (greater than 100.1), blood in stool per patient, dre, or tenesmus.) exclusion criteria: * chronic symptoms (\>14 days) * inability to follow- up (i.e. no telephone) * prisoner * likely non-infectious cause of diarrhea (crohn's disease, radiation colitis, irritable bowel syndrome, or celiac disease) * confirmed c. diff diarrhea * unable to provide written consent * non- english speaker